Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 9;356:j791.
doi: 10.1136/bmj.j791.

Serum Creatinine Elevation After Renin-Angiotensin System Blockade and Long Term Cardiorenal Risks: Cohort Study

Affiliations
Free PMC article

Serum Creatinine Elevation After Renin-Angiotensin System Blockade and Long Term Cardiorenal Risks: Cohort Study

Morten Schmidt et al. BMJ. .
Free PMC article

Abstract

Objective To examine long term cardiorenal outcomes associated with increased concentrations of creatinine after the start of angiotensin converting enzyme inhibitor/angiotensin receptor blocker treatment.Design Population based cohort study using electronic health records from the Clinical Practice Research Datalink and Hospital Episode Statistics.Setting UK primary care, 1997-2014.Participants Patients starting treatment with angiotensin converting enzyme inhibitors or angiotensin receptor blockers (n=122 363).Main outcome measures Poisson regression was used to compare rates of end stage renal disease, myocardial infarction, heart failure, and death among patients with creatinine increases of 30% or more after starting treatment against those without such increases, and for each 10% increase in creatinine. Analyses were adjusted for age, sex, calendar period, socioeconomic status, lifestyle factors, chronic kidney disease, diabetes, cardiovascular comorbidities, and use of other antihypertensive drugs and non-steroidal anti-inflammatory drugs.Results Among the 2078 (1.7%) patients with creatinine increases of 30% or more, a higher proportion were female, were elderly, had cardiorenal comorbidity, and used non-steroidal anti-inflammatory drugs, loop diuretics, or potassium sparing diuretics. Creatinine increases of 30% or more were associated with an increased adjusted incidence rate ratio for all outcomes, compared with increases of less than 30%: 3.43 (95% confidence interval 2.40 to 4.91) for end stage renal disease, 1.46 (1.16 to 1.84) for myocardial infarction, 1.37 (1.14 to 1.65) for heart failure, and 1.84 (1.65 to 2.05) for death. The detailed categorisation of increases in creatinine concentrations (<10%, 10-19%, 20-29%, 30-39%, and ≥40%) showed a graduated relation for all outcomes (all P values for trends <0.001). Notably, creatinine increases of less than 30% were also associated with increased incidence rate ratios for all outcomes, including death (1.15 (1.09 to 1.22) for increases of 10-19% and 1.35 (1.23 to 1.49) for increases of 20-29%, using <10% as reference). Results were consistent across calendar periods, across subgroups of patients, and among continuing users.Conclusions Increases in creatinine after the start of angiotensin converting enzyme inhibitor/angiotensin receptor blocker treatment were associated with adverse cardiorenal outcomes in a graduated relation, even below the guideline recommended threshold of a 30% increase for stopping treatment.

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: LAT and LS were supported by Wellcome Trust and MS by grants from A.P. Møller Foundation for the Advancement of Medical Science, Snedkermester Sophus Jacobsen and Hustru Astrid Jacobsens Fond, Christian og Ottilia Brorsons Rejseleg at for yngre videnskabsmænd og –kvinder; the Department of Clinical Epidemiology is involved in studies with funding from various companies as research grants to (and administered by) Aarhus University, but none of these studies has any relation to the present study; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Figures

None
Fig 1 Time dependent cardiorenal risks associated with creatinine increases ≥30% after renin-angiotensin system blockade
None
Fig 2 Cumulative mortality according to levels of creatinine increase after renin-angiotensin system blockade
None
Fig 3 Cardiorenal risks associated with levels of creatinine increase after renin-angiotensin system blockade

Comment in

Similar articles

See all similar articles

Cited by 24 articles

  • Lab monitoring and acute care utilization during initiation of renin angiotensin aldosterone inhibitors or diuretics in chronic kidney disease.
    Garlo KG, Bates DW, Seger DL, Fiskio JM, Charytan DM. Garlo KG, et al. Medicine (Baltimore). 2019 Dec;98(49):e17963. doi: 10.1097/MD.0000000000017963. Medicine (Baltimore). 2019. PMID: 31804307 Free PMC article. Clinical Trial.
  • [Austrian Consensus on High Blood Pressure 2019].
    Weber T, Arbeiter K, Ardelt F, Auer J, Aufricht C, Brandt MC, Dichtl W, Ferrari J, Föger B, Henkel M, Hohenstein-Scheibenecker K, Horn S, Kautzky-Willer A, Kepplinger E, Knoflach M, Koppelstätter C, Mache C, Marschang P, Mayer G, Metzler B, Oberbauer R, Obermair F, Obermayer-Pietsch B, Perl S, Pilz S, Prischl FC, Podczeck-Schweighofer A, Rebhandl E, Rohla M, Roller-Wirnsberger R, Saely CH, Siostrzonek P, Slany J, Stoschitzky K, Waldegger S, Wenzel RR, Weiss T, Wirnsberger G, Winhofer-Stöckl Y, Zweiker D, Zweiker R, Watschinger B; Österreichische Gesellschaft für Hypertensiologie; Österreichische Atherosklerosegesellschaft; Österreichische Diabetes Gesellschaft; Österreichische Gesellschaft für Internistische Angiologie; Österreichische Gesellschaft für Nephrologie; Österreichische Kardiologische Gesellschaft; Österreichische Gesellschaft für Neurologie; Österreichische Schlaganfall-Gesellschaft; Österr. Gesellschaft für Allgemeinmedizin; Österr. Gesellschaft für Geriatrie; Österreichische Gesellschaft für Endokrinologie und Stoffwechsel; Österreichische Gesellschaft für Innere Medizin; Österreichische Gesellschaft für Kinder- und Jugendheilkunde. Weber T, et al. Wien Klin Wochenschr. 2019 Nov;131(Suppl 6):489-590. doi: 10.1007/s00508-019-01565-0. Wien Klin Wochenschr. 2019. PMID: 31792659 German.
  • Kidney disease trials for the 21st century: innovations in design and conduct.
    Herrington WG, Staplin N, Haynes R. Herrington WG, et al. Nat Rev Nephrol. 2020 Mar;16(3):173-185. doi: 10.1038/s41581-019-0212-x. Epub 2019 Oct 31. Nat Rev Nephrol. 2020. PMID: 31673162 Review.
  • Risk factors associated with biochemically detected and hospitalised acute kidney injury in patients prescribed renin angiotensin system inhibitors.
    Mark PB, Papworth R, Ramparsad N, Tomlinson LA, Sawhney S, Black C, McConnachie A, McCowan C. Mark PB, et al. Br J Clin Pharmacol. 2020 Jan;86(1):121-131. doi: 10.1111/bcp.14141. Epub 2020 Jan 3. Br J Clin Pharmacol. 2020. PMID: 31663151
  • Managing hypertension in primary care.
    Waked K, Nagge J, Grindrod K. Waked K, et al. Can Fam Physician. 2019 Oct;65(10):725-729. Can Fam Physician. 2019. PMID: 31604742 Free PMC article. No abstract available.
See all "Cited by" articles

References

    1. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. 2016. http://www.nice.org.uk/guidance/cg127/chapter/1-recommendations#choosing-antihypertensive-drug-treatment-2.
    1. Lesogor A, Cohn JN, Latini R, et al. Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study. Eur J Heart Fail 2013;15:1236-44. 10.1093/eurjhf/hft089 pmid:23787721. - DOI - PubMed
    1. Schmidt M, Mansfield KE, Bhaskaran K, et al. Adherence to guidelines for creatinine and potassium monitoring and discontinuation following renin-angiotensin system blockade: a UK general practice-based cohort study. BMJ Open 2017;7:e012818 10.1136/bmjopen-2016-012818 pmid:28069618. - DOI - PMC - PubMed
    1. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?Arch Intern Med 2000;160:685-93. 10.1001/archinte.160.5.685 pmid:10724055. - DOI - PubMed
    1. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52. 10.1016/S0140-6736(97)01187-2 pmid:9074572. - DOI - PubMed

MeSH terms

Substances

Feedback